As a comprehensive global biotech company, Creative Biolabs provides a first class dual-targeting IgG (DT-IgG) service. Our aim is to leverage our years of experience in antibody engineering research to assist our customers with their preclinical and clinical programs development.
Our scientists can modify an antibody with two targets binding specificity, and thus this kind of Ab is named DT-IgG. This single bispecific antibody can save the cost and reduce the complexity of manufacturing, which is a popular strategy in preclinical and clinical studies. We provide DT-IgGs which can not only target a variety of tumor-associated antigens but also neutralize excrescent disease-related ligands and receptors to meet your specific requirements. Additionally, Creative Biolabs offers a series of validation tests of bispecific antibody. Our DT-IgGs can penetrate into tumors easily and perform the anti-tumor effect effectively.
Our dual targeting technology platform can be applied to bind the following targets:
